Developer docs
API playgroundTry for free, no card

Search company profiles

Evolyra Therapeutics

Full company profile

uuid00stwcs

Namestring
Evolyra Therapeutics
Legal namestring
Evolyra Therapeutics
Company typeenum
Private
Founded yearint
2025
Descriptiontext

Evolyra Therapeutics is a preclinical-stage biotechnology company developing next-generation adeno-associated virus (AAV) gene replacement therapies for limb-girdle muscular dystrophy types 2C (LGMD2C) and 2D (LGMD2D) — rare, progressive neuromuscular diseases with no approved treatments affecting approximately 20,000 people globally. Founded in August 2025 and headquartered in Richmond, Virginia, the company is built on a second-generation AAV vector platform engineered to deliver full-length functional genes to skeletal muscle tissue while eliminating the liver toxicity risks that have limited earlier gene therapy programs. Unlike Duchenne muscular dystrophy therapies that use partial gene replacement, Evolyra's approach delivers complete functional genes as a single-dose, long-term corrective infusion.

The company's core technology is a modular AAV platform explicitly designed for scalability across 20+ LGMD subtypes and beyond. Its translational infrastructure is anchored by a partnership with the GRASP-LGMD Consortium, which provides access to 500+ patients, natural history data, biomarkers, and clinical trial-ready sites, and by a clinical manufacturing agreement with Andelyn Biosciences (announced April 2026) leveraging Andelyn's AAV Curator Platform for IND-enabling studies and GMP production. The founding team comprises physician-scientists from Virginia Commonwealth University's Center for Inherited Myology Research, led by Dr. Nicholas E. Johnson (CEO), Kevin L. Passarello (COO), Dr. Melissa Hale (CTO), and Dr. Ellie Carrell (CSO).

Evolyra's revenue model is contingent on future commercialization of one-time gene therapy products for rare disease patients, consistent with premium orphan-drug pricing upon regulatory approval. The company is currently pre-revenue, having completed a $5 million seed round and actively raising a $20 million Series A to fund IND submission planned for H2 2026 and subsequent Phase I/II clinical trials. Go-to-market will occur through specialized rare disease treatment centers and hospital pharmacies, with clinical operations conducted through enterprise partnerships with clinical trial sites and patient consortiums.

Short descriptiontext

Evolyra Therapeutics is a preclinical biotechnology company developing second-generation AAV gene replacement therapies for limb-girdle muscular dystrophy types 2C and 2D, targeting a rare disease population of approximately 20,000 patients globally.

Operating statusenum
Operating
Ownership categoryenum
akta.pro rankint
HeadquartersUniversity Of Richmond, United States
HQ citystring
University Of Richmond
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
AAV gene therapy, gene replacement therapy, neuromuscular disease therapeutics, limb-girdle muscular dystrophy, rare disease biotechnology
Industry2 codes
PRIMARYHLAAACAA
AAV Vector Gene Therapy Developers
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAAACAE
Gene Therapy for Rare/Monogenic Diseases
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
NAICS code1 code
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Biological Products, (No Disgnostic Substances)2836
Product category
Gene Therapy Pharmaceuticals
No data
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Gene Therapy Product Sales
TypeOne Time License
Description

As a preclinical biotech company developing gene replacement therapies, Evolyra plans to generate revenue through commercialization of gene therapy treatments for LGMD. The company is currently in preclinical stages with IND submission planned for H2 2026.

biospace.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Technology or R&D, Personnel, Operations, Infrastructure, Supply Chain, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Evolyra Therapeutics is a preclinical biotechnology company developing a second-generation Adeno-Associated Virus (AAV) gene therapy platform engineered to deliver full-length functional genes directly to skeletal muscle while avoiding liver toxicity. Its lead therapeutic programs target Limb-Girdle Muscular Dystrophy types 2C (LGMD2C/LGMDR3) and 2D (LGMD2D/LGMDR5), designed as single-dose, long-term corrective treatments for these rare, currently untreatable neuromuscular diseases.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • Successful preclinical results demonstrating complete protein expression and muscle restoration in animal models
+1 more record
Product overview1 text field

Evolyra Therapeutics is a biotechnology company developing a platform-based portfolio of gene replacement therapies for Limb-Girdle Muscular Dystrophy (LGMD). The core offering consists of a second-generation AAV vector platform that enables safe, full-length gene delivery to muscle tissue, supporting pipeline programs targeting LGMD2C and LGMD2D subtypes. The modular platform is designed to scale across 20+ LGMD subtypes and beyond.

Product and service2 records
1Second-Generation AAV Vector Platform
CategoryGene Therapy Delivery Platform
Description

A next-generation Adeno-Associated Virus (AAV) gene therapy delivery platform engineered to deliver full-length functional genes directly to muscle tissue while avoiding liver toxicity, addressing safety limitations of earlier gene therapy approaches. The modular platform is designed to scale across 20+ LGMD subtypes.

2Gene Replacement Therapy for LGMD2C and LGMD2D
CategoryGene Therapy Product
Description

A single-dose, long-term corrective gene therapy targeting Limb-Girdle Muscular Dystrophy types 2C and 2D (also referred to as LGMDR3 and LGMDR5), designed to deliver complete functional genes for effective treatment of these rare neuromuscular diseases affecting approximately 20,000 patients globally.

Scale indicator6 records

Each record includes

Type, Value, Description, Source

Partnership4 partners
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2026-04-14
Description

Andelyn Biosciences partnered with Evolyra for clinical manufacturing of AAV gene therapies for LGMD types 2C and 2D. Andelyn will utilize its proprietary AAV Curator Platform to support IND-enabling studies and GMP manufacturing for Evolyra's programs.

2GRASP-LGMD Consortium
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Global network of clinicians, scientists, and patient advocates focused on accelerating LGMD research. Provides Evolyra access to clinical trial-ready infrastructure, natural history data, and patient voices that guide therapy development. Consortium includes 500+ patients providing biomarkers and disease progression tools.

evolyratherapeutics.com
Strategic tierSupportingTypeOthers
Description

Non-profit organization dedicated to improving quality of life for those living with muscular dystrophy. Founder Kathryn Bryant Knudson authored introduction to Evolyra highlighting the company's mission and approach.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Founding team members (Dr. Nicholas Johnson, Dr. Melissa Hale, Dr. Ellie Carrell) are affiliated with VCU's Center for Inherited Myology Research. Kevin Passarello serves as Entrepreneur-in-Residence. Provides research infrastructure and academic expertise.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers8 records
TypeBroad incumbent
Description

Pfizer commercializes Beqvez, an AAV gene therapy for hemophilia B, and has broader rare disease gene therapy capabilities. Operates as a large incumbent in the broader AAV gene therapy space and is a potential acquirer or competitor for the same patient populations and partnerships.

TypeDirect peer
Description

Solid Biosciences develops AAV gene therapies for Duchenne and other neuromuscular diseases, with programs spanning multiple subtypes. Comparable in modality (AAV), indication overlap, and clinical-stage development profile.

TypeDirect peer
Description

Sarepta is the leading commercial-stage gene therapy company for Duchenne muscular dystrophy (Elevidys) and other neuromuscular diseases. Direct overlap with Evolyra in muscle-targeted AAV gene therapy, patient population (muscular dystrophy), and rare disease commercialization strategy.

TypeBroad incumbent
Description

Regenxbio is an established AAV platform company with multiple partnered gene therapy programs across rare diseases. Comparable AAV vector technology and rare disease focus, but operates a broader portfolio rather than a single neuromuscular niche.

TypeEmerging player
Description

Lexeo is a clinical-stage gene therapy company focused on rare diseases including cardiac and neurological indications. Comparable in AAV modality and early-stage development strategy with overlapping patient advocacy-driven trial design.

TypeDirect peer
Description

Atamyo is a clinical-stage gene therapy company developing AAV-based treatments specifically for multiple LGMD subtypes (including 2C/R5 and 2D/R3). The closest direct peer in indication, modality, and target population.

TypeBroad incumbent
Description

AskBio is a clinical-stage AAV gene therapy platform with programs across neuromuscular and other rare diseases, owned by Bayer. Comparable AAV technology and rare disease focus; operates a broader pipeline rather than LGMD-specific focus.

TypeEmerging player
Description

Taysha develops AAV-based gene therapies for rare CNS and neuromuscular diseases. Comparable in AAV platform approach and rare disease focus, though with different lead indications.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles4 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Evolyra Therapeutics

Gene Therapy Pharmaceuticalsevolyratherapeutics.com

Evolyra Therapeutics is a preclinical biotechnology company developing second-generation AAV gene replacement therapies for limb-girdle muscular dystrophy types 2C and 2D, targeting a rare disease population of approximately 20,000 patients globally.

What Evolyra Therapeutics does

Evolyra Therapeutics is a preclinical-stage biotechnology company developing next-generation adeno-associated virus (AAV) gene replacement therapies for limb-girdle muscular dystrophy types 2C (LGMD2C) and 2D (LGMD2D) — rare, progressive neuromuscular diseases with no approved treatments affecting approximately 20,000 people globally. Founded in August 2025 and headquartered in Richmond, Virginia, the company is built on a second-generation AAV vector platform engineered to deliver full-length functional genes to skeletal muscle tissue while eliminating the liver toxicity risks that have limited earlier gene therapy programs. Unlike Duchenne muscular dystrophy therapies that use partial gene replacement, Evolyra's approach delivers complete functional genes as a single-dose, long-term corrective infusion.

The company's core technology is a modular AAV platform explicitly designed for scalability across 20+ LGMD subtypes and beyond. Its translational infrastructure is anchored by a partnership with the GRASP-LGMD Consortium, which provides access to 500+ patients, natural history data, biomarkers, and clinical trial-ready sites, and by a clinical manufacturing agreement with Andelyn Biosciences (announced April 2026) leveraging Andelyn's AAV Curator Platform for IND-enabling studies and GMP production. The founding team comprises physician-scientists from Virginia Commonwealth University's Center for Inherited Myology Research, led by Dr. Nicholas E. Johnson (CEO), Kevin L. Passarello (COO), Dr. Melissa Hale (CTO), and Dr. Ellie Carrell (CSO).

Evolyra's revenue model is contingent on future commercialization of one-time gene therapy products for rare disease patients, consistent with premium orphan-drug pricing upon regulatory approval. The company is currently pre-revenue, having completed a $5 million seed round and actively raising a $20 million Series A to fund IND submission planned for H2 2026 and subsequent Phase I/II clinical trials. Go-to-market will occur through specialized rare disease treatment centers and hospital pharmacies, with clinical operations conducted through enterprise partnerships with clinical trial sites and patient consortiums.

Evolyra Therapeutics firmographics

Firmographics
Name
Evolyra Therapeutics
Legal name
Evolyra Therapeutics
Website
https://evolyratherapeutics.com
Company type
Private
Founded year
2025
Operating status
Operating
Short description
Evolyra Therapeutics is a preclinical biotechnology company developing second-generation AAV gene replacement therapies for limb-girdle muscular dystrophy types 2C and 2D, targeting a rare disease population of approximately 20,000 patients globally.
Ownership category
akta.pro rank

Evolyra Therapeutics industry classification

Industry
Product category
Gene Therapy Pharmaceuticals
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAAACAA
AAV Vector Gene Therapy Developers
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAAACAE
Gene Therapy for Rare/Monogenic Diseases
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)

Keywords

  • AAV gene therapy
  • Gene replacement therapy
  • Neuromuscular disease therapeutics
  • Limb-girdle muscular dystrophy
  • Rare disease biotechnology

Where Evolyra Therapeutics is headquartered

Location

Headquarters

HQ city
University Of Richmond
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Evolyra Therapeutics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Infrastructure, Supply Chain, Marketing or Sales

Revenue model

  1. Gene Therapy Product Sales: As a preclinical biotech company developing gene replacement therapies, Evolyra plans to generate revenue through commercialization of gene therapy treatments for LGMD. The company is currently in preclinical stages with IND submission planned for H2 2026.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Evolyra Therapeutics product offering

Product offering

Core offering

Evolyra Therapeutics is a preclinical biotechnology company developing a second-generation Adeno-Associated Virus (AAV) gene therapy platform engineered to deliver full-length functional genes directly to skeletal muscle while avoiding liver toxicity. Its lead therapeutic programs target Limb-Girdle Muscular Dystrophy types 2C (LGMD2C/LGMDR3) and 2D (LGMD2D/LGMDR5), designed as single-dose, long-term corrective treatments for these rare, currently untreatable neuromuscular diseases.

Product overview

Evolyra Therapeutics is a biotechnology company developing a platform-based portfolio of gene replacement therapies for Limb-Girdle Muscular Dystrophy (LGMD). The core offering consists of a second-generation AAV vector platform that enables safe, full-length gene delivery to muscle tissue, supporting pipeline programs targeting LGMD2C and LGMD2D subtypes. The modular platform is designed to scale across 20+ LGMD subtypes and beyond.

Differentiator

Problem solved

Functional benefit

Products and services

  • Second-Generation AAV Vector Platform A next-generation Adeno-Associated Virus (AAV) gene therapy delivery platform engineered to deliver full-length functional genes directly to muscle tissue while avoiding liver toxicity, addressing safety limitations of earlier gene therapy approaches. The modular platform is designed to scale across 20+ LGMD subtypes.
  • Gene Replacement Therapy for LGMD2C and LGMD2D A single-dose, long-term corrective gene therapy targeting Limb-Girdle Muscular Dystrophy types 2C and 2D (also referred to as LGMDR3 and LGMDR5), designed to deliver complete functional genes for effective treatment of these rare neuromuscular diseases affecting approximately 20,000 patients globally.

Quantifiable outcome

  • Successful preclinical results demonstrating complete protein expression and muscle restoration in animal models
  • +1 more outcomes

Companies that use Evolyra Therapeutics

Customer profile

Segments1 record

Ideal customer profiles1 record

Evolyra Therapeutics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Evolyra Therapeutics partnerships and signals

Strategic signal

Partnerships

Four partnerships are on record, tiered core and supporting.

  • Andelyn BiosciencescoreTechnology or Integration · 14 April 2026Andelyn Biosciences partnered with Evolyra for clinical manufacturing of AAV gene therapies for LGMD types 2C and 2D. Andelyn will utilize its proprietary AAV Curator Platform to support IND-enabling studies and GMP manufacturing for Evolyra's programs.
  • GRASP-LGMD ConsortiumcoreStrategic or Co-development PartnerGlobal network of clinicians, scientists, and patient advocates focused on accelerating LGMD research. Provides Evolyra access to clinical trial-ready infrastructure, natural history data, and patient voices that guide therapy development. Consortium includes 500+ patients providing biomarkers and disease progression tools.
  • The Speak FoundationsupportingOthersNon-profit organization dedicated to improving quality of life for those living with muscular dystrophy. Founder Kathryn Bryant Knudson authored introduction to Evolyra highlighting the company's mission and approach.
  • Virginia Commonwealth UniversitycoreStrategic or Co-development PartnerFounding team members (Dr. Nicholas Johnson, Dr. Melissa Hale, Dr. Ellie Carrell) are affiliated with VCU's Center for Inherited Myology Research. Kevin Passarello serves as Entrepreneur-in-Residence. Provides research infrastructure and academic expertise.

Scale indicators6 records

Recent moves6 records

Expansion highlights5 records

Evolyra Therapeutics competitors and assessment

Company assessment

Broad incumbents

  • Pfizer: Pfizer commercializes Beqvez, an AAV gene therapy for hemophilia B, and has broader rare disease gene therapy capabilities. Operates as a large incumbent in the broader AAV gene therapy space and is a potential acquirer or competitor for the same patient populations and partnerships.
  • Regenxbio: Regenxbio is an established AAV platform company with multiple partnered gene therapy programs across rare diseases. Comparable AAV vector technology and rare disease focus, but operates a broader portfolio rather than a single neuromuscular niche.
  • Asklepios BioPharmaceutical (AskBio): AskBio is a clinical-stage AAV gene therapy platform with programs across neuromuscular and other rare diseases, owned by Bayer. Comparable AAV technology and rare disease focus; operates a broader pipeline rather than LGMD-specific focus.

Direct peers

  • Solid Biosciences: Solid Biosciences develops AAV gene therapies for Duchenne and other neuromuscular diseases, with programs spanning multiple subtypes. Comparable in modality (AAV), indication overlap, and clinical-stage development profile.
  • Sarepta Therapeutics: Sarepta is the leading commercial-stage gene therapy company for Duchenne muscular dystrophy (Elevidys) and other neuromuscular diseases. Direct overlap with Evolyra in muscle-targeted AAV gene therapy, patient population (muscular dystrophy), and rare disease commercialization strategy.
  • Atamyo Therapeutics: Atamyo is a clinical-stage gene therapy company developing AAV-based treatments specifically for multiple LGMD subtypes (including 2C/R5 and 2D/R3). The closest direct peer in indication, modality, and target population.

Emerging players

  • Lexeo Therapeutics: Lexeo is a clinical-stage gene therapy company focused on rare diseases including cardiac and neurological indications. Comparable in AAV modality and early-stage development strategy with overlapping patient advocacy-driven trial design.
  • Taysha Gene Therapies: Taysha develops AAV-based gene therapies for rare CNS and neuromuscular diseases. Comparable in AAV platform approach and rare disease focus, though with different lead indications.

Market position

Strengths5 records

Weaknesses4 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

Evolyra Therapeutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Evolyra Therapeutics leadership team

Management profile

Number of profiles

Profiles4 records

Evolyra Therapeutics funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Evolyra Therapeutics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Evolyra Therapeutics

What does Evolyra Therapeutics do?

Evolyra Therapeutics is a preclinical biotechnology company developing a second-generation Adeno-Associated Virus (AAV) gene therapy platform engineered to deliver full-length functional genes directly to skeletal muscle while avoiding liver toxicity. Its lead therapeutic programs target Limb-Girdle Muscular Dystrophy types 2C (LGMD2C/LGMDR3) and 2D (LGMD2D/LGMDR5), designed as single-dose, long-term corrective treatments for these rare, currently untreatable neuromuscular diseases.

Is Evolyra Therapeutics a public or private company?

Evolyra Therapeutics is a private company. It is classified as venture growth investor backed and is currently operating.

When was Evolyra Therapeutics founded?

Evolyra Therapeutics was founded in 2025.

Where is Evolyra Therapeutics based?

Evolyra Therapeutics is headquartered in University Of Richmond, United States, in the North America region.

How does Evolyra Therapeutics make money?

One revenue line is on record: gene Therapy Product Sales.

Who are Evolyra Therapeutics's main competitors?

Broad incumbents on record are Pfizer, Regenxbio and Asklepios BioPharmaceutical (AskBio). Direct peers are Solid Biosciences, Sarepta Therapeutics and Atamyo Therapeutics. Emerging players are Lexeo Therapeutics and Taysha Gene Therapies.

Does Evolyra Therapeutics have an API?

No public API is recorded for Evolyra Therapeutics.

What industry is Evolyra Therapeutics in?

Evolyra Therapeutics's product category is Gene Therapy Pharmaceuticals. Its primary akta.pro industry code is HLAAACAA, AAV Vector Gene Therapy Developers, with a secondary code of HLAAACAE, Gene Therapy for Rare/Monogenic Diseases. Its NAICS code is 541714 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
BioSpaceAndelyn Biosciences Partners with Evolyra Therapeutics for the Clinical Manufacturing of Gene Therapies for the Treatment of Limb-Girdle Muscular DystrophiesAndelyn Biosciences has partnered with Evolyra Therapeutics to manufacture clinical-grade AAV gene therapies for treating types 2C and 2D Limb-Girdle Muscular Dystrophies, utilizing Andelyn's proprietary AAV Curator Platform to support IND-enabling studies and GMP manufacturing. Evolyra has achieved successful preclinical results demonstrating complete protein expression and muscle restoration in animal models, with plans to submit an IND application in the second half of 2026 followed by Phase I/II clinical trials. Evolyra recently completed a $5 million seed funding round and is currently raising a $20 million Series A to advance these programs targeting an $11 billion market representing approximately 20,000 patients worldwide.PR NewswireAndelyn Biosciences Partners with Evolyra Therapeutics for the Clinical Manufacturing of Gene Therapies for the Treatment of Limb-Girdle Muscular DystrophiesAndelyn Biosciences has partnered with Evolyra Therapeutics to manufacture clinical-grade AAV gene therapies for treating types 2C and 2D Limb-Girdle Muscular Dystrophies, utilizing Andelyn's proprietary AAV Curator® Platform. Evolyra plans to submit an Investigational New Drug application in the second half of 2026 followed by Phase I/II clinical trials, having recently completed a $5 million seed funding round and currently raising a $20 million Series A. The initial programs target LGMDR3 and LGMDR5, representing an $11 billion market opportunity with approximately 20,000 patients worldwide.Fastdata极数美国基因疗法研究商Evolyra获得500万美元种子轮融资 – Fastdata极数Evolyra, a gene therapy research company, secured $5 million in seed funding. The company develops gene therapies for rare neuromuscular diseases, initially focusing on limb-girdle muscular dystrophy, and is advancing a muscle-targeted AAV vector platform.